[EirGenix] The company's biosimilar drug "EIRGASUN vial 420 mg" approved by the NHIA for National Health Insurance coverage
NQ Score
0/100
N1 Content Completeness
9
AI Summary (NQ-processed)
EirGenix's biosimilar drug EIRGASUN (for breast and stomach cancer) has been approved for NHI coverage at NT$24,240 per vial, effective June 1.